Navigation Links
Real-World Studies of Carotid Artery Stenting Demonstrate Results Comparable to Guidelines for Patients Treated With Surgery
Date:10/23/2007

WASHINGTON, Oct. 23 /PRNewswire-FirstCall/ -- Two carotid stenting trials examining outcomes in real-world patients demonstrated for the first time results that are comparable to guidelines established by the American Heart Association (AHA)(1) for patients treated with carotid artery surgery. The results of these studies were presented today in a late-breaking clinical trials session at the Cardiovascular Research Foundation's 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium by William Gray, M.D., FACC, of Columbia University Medical Center in New York.

Patients treated with carotid stents in Abbott's CAPTURE 2 (Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events) and EXACT(TM) (Emboshield and Xact Post Approval Carotid Stent Trial) post-marketing trials, which enrolled 4,111 patients, demonstrated 30 day patient outcome results that are comparable to the AHA outcome guidelines for patients less than 80 years old who undergo carotid surgery (carotid endarterectomy). These guidelines recommend stroke and death rates that are within 3% for patients without symptoms of stroke (asymptomatic) and 6% for patients with symptoms of stroke (symptomatic).

"With these two very large, well-conducted, real-world carotid artery stenting trials, not only has carotid stenting achieved a comparable outcome to guidelines established for patients who undergo carotid surgery, but it also did so in a population of patients who are at high risk for experiencing adverse events from surgery," said Dr. Gray. "This is significant because this is the first time physicians have achieved results in high surgical risk candidates that are comparable to the long-standing guidelines that were established for lower surgical risk candidates, demonstrating that stenting can provide a reliable non-surgical alternative for patients facing the difficult decision of how to manage their carotid artery disease."

In 1998, the American
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Studies On Hearing Loss Discovers New Causes
2. Broccoli Found to Block Cancer Progression In Both Animal and Human Studies
3. Studies Advocate Natural Form Of Vitamin E
4. Cure For Autism Could Be Established Through Hamster Studies
5. Despite More Studies Researchers Are Still Confound With ADHD
6. Studies Show Brain becomes Less Specialized With Age
7. ISB To Establish Research Chair On Real Estate And Urban Studies
8. Studies Show Combination Drugs As A Poor Substitute For Anti-Coagulants In Stroke
9. Further Studies Needed To Completely Understand About Ventricular Fibrillation
10. Studies Report Mammograms Unsafe
11. Six Indians Win Australian Studies Fellowships

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... Nov. 20 The American ...fy health care reform legislation released this we... insurance individual coverage mandate. The actuar... will minimize adverse selection stemming from mor... the bill. ,, "The individual mandate language ...
(Date:11/20/2009)..., Nov. 20 Following a recall by Un...oved from sale Shedd,s Country Crock ® Side D...ntry Crock ® Side Dishes DELUXE Four Cheese P... The following code dates and UPCs are affected: ,...UXE Cheddar Broccoli Rice 21 oz, UPC 027400218316,...
(Date:11/20/2009)....J., Nov. 20 Rates of in...peaked in late October, but the pandemic flu virus...all age groups, including the elderly, according t...NYSE: DGX ), the world,s leading provider of dia...In its most recent Quest Diagnostics Health Trends...
(Date:11/20/2009)... Nov. 20 Centene Corpo... present at the Bank of America Merrill Lynch 2009... at the Crowne Plaza Hotel Times Square in New Yor...mber 2nd at 8:30 a.m. Eastern Time. Investors and ...webcast of Centene,s presentation at: http://www....
(Date:11/20/2009)..., N.C., Nov. 20 Samuel ...redefine what it means to be "happy" during the ho...a specialty in family counseling and chair of the ..., Gladding says research shows that it is the pres...ven depression during the holidays. ,, That,s w...
Breaking Medicine News(10 mins):Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3Health News:Why Holidays Don't Have To Be 'Happy' 2
... antibody drug to chemotherapy looks promising for...ding to Mayo Clinic researchers working with the N...://ncctg.mayo.edu/ ). Results of this interim anal...tients responded to treatment that included the dr...
...surgeries, researchers report , , FRIDAY,...ng rates, the number of mastectomies performed on ... Mayo Clinic now reports. , The increase coincid... at the American Society of Clinical Oncology (ASC...
... IDMI ) today announced that clinical data presen...idates will be made at the upcoming 44th,American .... Data presented,at the meeting will support impro... Presentation highlights are as follows:, L-MTP-P...
...s with metal complexes, scientists at The Wistar I...itor capable of blocking a biochemical pathway tha...d on studies in human melanoma cells, the research... of the study, to be published in the May 16 issue...
...y hospitals associated with Fox Chase Cancer Cente...een a major academic cancer center, where most new...spitals, where most care is provided, is a highly ...in Philadelphia, first established its network of ...
...edication also known by the trade name Celebrex, h...eration measurement of precancerous lesions in the... Texas M. D. Anderson Cancer Center. This finding ...is the first large randomized trial of Celebrex in...
Other Medicine News:Health News:Adding epratuzumab to standard therapy 2Health News:Mastectomies on the Increase 2Health News:Mastectomies on the Increase 3Health News:IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting 2Health News:IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting 3Health News:Novel enzyme inhibitor paves way for new cancer drug 2Health News:Novel enzyme inhibitor paves way for new cancer drug 3Health News:Partnership of academic centers and community hospitals effective model for disseminating advances 2Health News:Partnership of academic centers and community hospitals effective model for disseminating advances 3Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 3
(Date:11/19/2009)..., Nov. 19 In a series of...nce, Heska Corporation (Nasdaq: HSKA ) ("Heska" o... new and improved website. The upgraded site is t...d programming to align the site with the company,s...(Logo: http://www.newscom.com/cgi-bin/prnh/20000...
(Date:11/19/2009)...., Nov. 19 The D e al...of its Most Admired Corporate Dealmakers for the s... as its Most Admired Dealmaker in pharma/biotech f...s and divestitures since January 2006. ,, Over ...portfolio with a focus on high-growth, innovation-...
(Date:11/19/2009)...., Nov. 19 Mach 7 Technologies, ...care image management solutions, and QStar Technol...ed PACS- neutral archive solution through their co...n international leader in providing digital image ...l industry. Under the agreement, Data Distributin...
Breaking Medicine Technology:Heska Announces Launch of New Website 2Heska Announces Launch of New Website 3The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 2Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 3Mach 7 Technologies and QStar Sign Agreement to Deliver PACS-Neutral Solutions Through Mutual Channel Partner, Data Distributing 4NexInfo Solutions Inc Selected by Beckman Coulter to Design and Streamline Global Sales 26 Operations Planning Processes 13597 1NexInfo Solutions Inc Selected by Beckman Coulter to Design and Streamline Global Sales 26 Operations Planning Processes 13597 2NexInfo Solutions Inc Selected by Beckman Coulter to Design and Streamline Global Sales 26 Operations Planning Processes 13597 3Hypertronics Circular HyperGrip 28R 29 Connectors Selected for Biosense Websters CARTO 28R 29 3 Navigation System 54663 1Hypertronics Circular HyperGrip 28R 29 Connectors Selected for Biosense Websters CARTO 28R 29 3 Navigation System 54663 2US born Asian American women more likely to think about attempt suicide 54659 1US born Asian American women more likely to think about attempt suicide 54659 2US born Asian American women more likely to think about attempt suicide 54659 3
...nd the European Organisation for the Research and ...llow-up results from the landmark Phase III,trial ...titute of Canada,(NCIC) that showed the combinatio...les and radiation therapy significantly prolonged,...(GBM) versus radiation,treatment alone and that a ...
... 6211 for the Potential Treatment of Pa...nd MUMBAI, India, Oct. 30 Eli,Lilly and Company (...nto an,agreement with Glenmark Pharmaceuticals S.A...rmaceuticals Limited India (GPL). Under the terms,... a portfolio of transient,receptor potential vanil...
Other Medicine Technology:Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme 2Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme 3Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme 4Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme 5Lilly and Glenmark Pharmaceuticals Announce License Agreement 2Lilly and Glenmark Pharmaceuticals Announce License Agreement 3Lilly and Glenmark Pharmaceuticals Announce License Agreement 4Lilly and Glenmark Pharmaceuticals Announce License Agreement 5
...ORE-TEX Stretch Vascular Grafts have met the chall...ecognized for exceptional performance and quality,...eons worldwide. These grafts require no preclottin...and ensure utmost thrombectomy safety. The GORE-TE...
...oday's evolving techniques for vascular surgery, a... require that new, specialized types of graft be d...d biocompatible, but also available in varying siz.... GORE-TEX Vascular Graft has long been the prosth...
...ORE-TEX Vascular Grafts have met the challenges of...5 years. Recognized for exceptional performance an...owned surgeons worldwide. These grafts require no ...nfection, and assure utmost thrombectomy safety. T...
...ORE-TEX® Vascular Grafts have met the challeng...ver 25 years. Recognized for exceptional performan...f renowned surgeons worldwide. These grafts requir... of infection, and assure utmost thrombectomy safe...
Medicine Products: